What Does ER-Positive, PR-Negative IDC Mean for Treatment?

It is common and understandably confusing to receive pathology results that are positive for one hormone receptor but negative for another. If your invasive ductal carcinoma is estrogen receptor (ER) positive but progesterone receptor (PR) negative, it means your cancer cells use estrogen to fuel their growth, but fewer than 1% of the cells show receptors for progesterone, falling below the standard laboratory positive threshold ^[1].

This is usually a recognized biological subtype rather than a testing error ^[2]. However, because receptor testing can occasionally be affected by how the tissue was handled or by variations within the tumor, your care team may review the pathology if the results seem mismatched with other tumor features ^[3]. While PR-negative disease can have different biology than cancer that is positive for both receptors, it is not automatically a “high-risk” diagnosis ^[4]. Most importantly, because your tumor is ER-positive, hormone-blocking therapies remain a cornerstone of reducing your recurrence risk ^[5].

Why is PR negative when ER is positive?

Normally, when estrogen attaches to an estrogen receptor in a cell, it triggers the cell to produce progesterone receptors. Because of this chain reaction, the two receptors usually appear together ^[2]. When a tumor is ER-positive but PR-negative, it indicates that the estrogen pathway is acting differently ^[6]. Research suggests this can happen if the specific gene responsible for making PR (the PGR gene) is lost or silenced ^[6]. It is also thought that some tumors rely on alternative growth pathways or have specific gene mutations that interfere with PR production ^[7].

Does PR-negative mean the cancer is more aggressive?

On a population level, studies show that ER-positive/PR-negative tumors sometimes have slightly more aggressive features than tumors that are positive for both receptors ^[8]. For example, they are more often associated with a higher tumor grade (how abnormal the cells look under a microscope) or lymph node involvement ^[8]. In large cancer registries, groups of patients with ER+/PR- breast cancer had slightly less favorable long-term outcomes on average than those with ER+/PR+ cancer ^[4][9].

However, population statistics cannot predict your individual outcome. “More aggressive on average” does not mean “high risk for you.” Your individual prognosis depends heavily on your specific stage and the treatments you receive ^[10]. Furthermore, ER-positive/PR-negative cancer still generally has much better outcomes than cancers that are negative for both receptors ^[4].

The Big Picture: Integrating Other Factors

Your care team will not base your treatment or prognosis on your PR status alone. They will look at several interacting factors to build a personalized plan:

• Stage and Tumor Burden: The size of the tumor and whether cancer cells have spread to nearby lymph nodes (known as your pathologic nodal stage, which is based on tissue removed during surgery) are among the strongest predictors of your overall outcome ^[10][8].
• HER2 Status: HER2 is another protein that can drive cancer growth. If your tumor is HER2-positive, anti-HER2 targeted therapies may be recommended, which fundamentally shifts the treatment approach ^[11].
• Ki-67 and Grade: Ki-67 is a test that estimates how fast cancer cells are dividing. Higher grade or high Ki-67 indicates faster-growing cells, which provides context for your care team ^[12]. However, Ki-67 testing has substantial laboratory variability, so it is never used as a stand-alone rule for deciding treatment ^[10].
• Genomic Risk (e.g., Oncotype DX): For certain patients with early-stage, HER2-negative disease, doctors often use genomic tests that look at the activity of a group of genes within the tumor. ER+/PR- tumors are statistically more likely to have higher genomic recurrence scores ^[13]. Tests like this can help estimate recurrence risk and the possible benefit of adding chemotherapy, but they are always interpreted alongside your age, menopausal status, and tumor size ^[14][15].

What This Means for Endocrine Therapy

Endocrine therapy (hormone-blocking medication like tamoxifen or aromatase inhibitors) is standard care for ER-positive breast cancer ^[5]. Validated testing showing that your tumor is ER-positive is the primary rationale for this treatment ^[5].

The exact percentage of your ER positivity matters. Most ER+/PR- tumors have strong ER expression. However, if your tumor is ER-low positive (meaning only 1% to 10% of cells show estrogen receptors), the expected benefit from endocrine therapy may be more limited or uncertain ^[5].

For most ER-positive tumors, even when PR is negative, endocrine therapy remains highly valuable for reducing the risk of recurrence ^[5][16]. While average responsiveness to these therapies can be slightly lower in PR-negative tumors compared to PR-positive tumors ^[2][17], your doctors will not withhold hormone therapy simply because the PR is negative ^[5]. The specific medication chosen will depend on your menopausal status, bone health, and overall risk profile, rather than your PR status alone ^[16][18].